About this episode
Ozempic is being hailed as “the end of the Obesity Epidemic.” This week, Mike and Aubrey dig through the sensational claims. But will they make it past the caveats?
Links:
- How a Canadian scientist and a venomous lizard helped pave the way for Ozempic
- The Discovery and Development of Liraglutide and Semaglutide
- Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor
- Insurers clamping down on doctors who prescribe Ozempic for weight loss
- Ozempic prescriptions can be easy to get online. Its popularity for weight loss is hurting those who need it most
- Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: real-world evidence from a Mediterranean area
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
- Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
- Safety of Semaglutide
- Semaglutide for the treatment of overweight and obesity: A review
- Once-Weekly Semaglutide in Adolescents with Obesity
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
- Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States
- Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data
Thanks to Doctor Dreamchip for our lovely theme song!
Get every episode summarized
Each time Maintenance Phase publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
